ABBOTT LABORATORIES (ABT) Share buybacks
- Total buybacks · last 12 months (USD): Value $793.00M; Formula and calculation Trailing-year cash paid for share repurchases. Period ending 2026-03-31..
- Buyback yield · 12 months: Value (m); Formula and calculation Cash paid for share repurchases / current market cap. Period ending 2026-03-31..
Share buybacks
Overview →Financial period ending 2026-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total buybacks · last 12 months (USD) | $793.00M | Trailing-year cash paid for share repurchases. Period ending 2026-03-31. |
| Buyback yield · 12 months | (m) | Cash paid for share repurchases / current market cap. Period ending 2026-03-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Buybacks · 12 months | 793.00M USD | Payments for Repurchase of Common Stock |
| Market cap | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total buybacks | Market cap (USD) | Buyback yield |
|---|---|---|---|
| 2026-03-31 | $793.00M | (m) | (m) |
| 2025-12-31 | $893.00M | (m) | (m) |
| 2025-09-30 | $906.00M | (m) | (m) |
| 2025-06-30 | $1.35B | (m) | (m) |
| 2025-03-31 | $1.35B | (m) | (m) |
| 2024-12-31 | $1.29B | (m) | (m) |
| 2024-09-30 | $1.24B | (m) | (m) |
| 2024-06-30 | $490.00M | (m) | (m) |
| 2024-03-31 | $913.00M | (m) | (m) |
| 2023-12-31 | $1.23B | (m) | (m) |
| 2023-09-30 | $1.65B | (m) | (m) |
| 2023-06-30 | $2.45B | (m) | (m) |
| 2023-03-31 | $2.03B | (m) | (m) |
| 2022-12-31 | $3.79B | (m) | (m) |
| 2022-09-30 | $4.08B | (m) | (m) |
| 2022-06-30 | $3.87B | (m) | (m) |
| 2022-03-31 | $4.33B | (m) | (m) |
| 2021-12-31 | $2.30B | (m) | (m) |
| 2021-09-30 | $1.49B | (m) | (m) |
| 2021-06-30 | $909.00M | (m) | (m) |
| 2021-03-31 | $442.00M | (m) | (m) |
| 2020-12-31 | $403.00M | (m) | (m) |
| 2020-09-30 | $738.00M | (m) | (m) |
| 2020-06-30 | $737.00M | (m) | (m) |
| 2020-03-31 | $737.00M | (m) | (m) |
| 2019-12-31 | $718.00M | (m) | (m) |
| 2019-09-30 | $326.00M | (m) | (m) |
| 2019-06-30 | $328.00M | (m) | (m) |
| 2019-03-31 | $327.00M | (m) | (m) |
| 2018-12-31 | $238.00M | (m) | (m) |
| 2018-09-30 | $145.00M | (m) | (m) |
| 2018-06-30 | $150.00M | (m) | (m) |
| 2018-03-31 | $150.00M | (m) | (m) |
| 2017-12-31 | $117.00M | (m) | (m) |
| 2017-09-30 | $106.00M | (m) | (m) |
| 2017-06-30 | $100.00M | (m) | (m) |
| 2017-03-31 | $98.00M | (m) | (m) |
| 2016-12-31 | $522.00M | (m) | (m) |
| 2016-09-30 | $1.41B | (m) | (m) |
| 2016-06-30 | $1.41B | (m) | (m) |
| 2016-03-31 | $1.41B | (m) | (m) |
| 2015-12-31 | $2.24B | (m) | (m) |
| 2015-09-30 | $1.35B | (m) | (m) |
| 2015-06-30 | $1.35B | (m) | (m) |
| 2015-03-31 | $1.35B | (m) | (m) |
| 2014-12-31 | $2.19B | (m) | (m) |
| 2014-09-30 | $2.23B | (m) | (m) |
| 2014-06-30 | $2.58B | (m) | (m) |
| 2014-03-31 | $2.87B | (m) | (m) |
| 2013-12-31 | $1.60B | (m) | (m) |
| 2013-09-30 | $2.21B | (m) | (m) |
| 2013-06-30 | $1.86B | (m) | (m) |
| 2013-03-31 | $2.30B | (m) | (m) |
| 2012-12-31 | $2.36B | (m) | (m) |
| 2012-09-30 | $1.73B | (m) | (m) |
| 2012-06-30 | $1.73B | (m) | (m) |
| 2012-03-31 | $992.94M | (m) | (m) |
| 2011-12-31 | $77.01M | (m) | (m) |
| 2011-09-30 | $75.08M | (m) | (m) |
| 2011-06-30 | $76.82M | (m) | (m) |
| 2011-03-31 | $77.21M | (m) | (m) |
| 2010-12-31 | $866.83M | (m) | (m) |
| 2010-09-30 | $867.13M | (m) | (m) |
| 2010-06-30 | $865.41M | (m) | (m) |
| 2010-03-31 | $864.76M | (m) | (m) |
| 2009-12-31 | $826.35M | (m) | (m) |
| 2009-09-30 | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) |
| 2009-03-31 | (m) | (m) | (m) |
| 2008-12-31 | $1.08B | (m) | (m) |
| 2008-09-30 | (m) | (m) | (m) |
| 2008-06-30 | (m) | (m) | (m) |
| 2007-12-31 | $1.06B | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |